Welcome to our dedicated page for Positron news (Ticker: POSC), a resource for investors and traders seeking the latest updates and insights on Positron stock.
Positron Corporation (POSC) delivers specialized cardiac PET imaging solutions that redefine nuclear cardiology diagnostics. This news hub provides investors and medical professionals with authoritative updates on technological advancements, clinical research partnerships, and regulatory developments shaping the future of cardiac care.
Access real-time announcements about product innovations, strategic collaborations, and peer-reviewed study results directly impacting coronary artery disease detection. Our curated news collection ensures you stay informed about POSC's leadership in radiation-reduced imaging systems and quantitative diagnostic tools trusted by cardiology practices worldwide.
Key updates include milestones in myocardial perfusion imaging technology, FDA clearances, and healthcare ecosystem integrations. Discover how POSC's dedicated PET systems continue to set industry benchmarks through enhanced diagnostic accuracy and operational efficiency improvements.
Bookmark this page for continuous access to verified press releases and analysis on POSC's role in advancing nuclear medicine. Regularly updated content helps stakeholders make informed decisions about this pioneering medical technology innovator.
Positron (OTC: POSC) has entered an agreement to acquire the FDA 510(k) clearance for the NeuSight PET-CT from Neusoft Medical Systems' subsidiary. This acquisition enables Positron to immediately market and sell the NeuSight PET-CT 64 slice imaging system and facilitates future FDA clearances for their Affinity PET-CT 4D 64 slice system. Adel Abdullah, President of Positron, emphasized that this milestone will significantly enhance their product line, which is vital for both oncology and nuclear cardiology. Positron aims to offer advanced PET-CT technology to healthcare practices, supported by Neusoft's extensive R&D expertise.
Positron Corporation (OTC: POSC) has entered a Clinical Study/Research Agreement with Ochsner Clinic Foundation for its new Affinity™ PET-CT 4D device. This agreement facilitates the collection of safety and efficacy data, crucial for obtaining an Investigational Device Exemption (IDE) from the FDA. The independent Institutional Review Board has approved all study procedures, allowing preparations for patient scans to begin post-IDE approval. The company aims for completion of the clinical study and FDA certification within 60 days, marking a significant step toward commercialization.
Positron Corporation (OTC: POSC) announces a collaboration with Dr. Robert Bober and Ochsner Health for a clinical study of its new Affinity PET-CT 4D imaging device. This FDA-compliant study, commencing mid-January 2023, aims to evaluate the device's image quality and performance in cardiac PET imaging. Dr. Bober's leadership is pivotal for gathering empirical data essential for marketing the system. Following completion and FDA 510k certification, Positron intends to commercialize the device in Q1 2023, targeting nuclear cardiology and oncology markets.
Positron Corporation (OTC: POSC) has announced the purchase of its first Affinity PET-CT system from Neusoft Medical Systems, which is currently in transit to the U.S. for validation. This marks a crucial step in launching the device, aimed at cardiac and oncology imaging. The company plans to reveal details about participating hospitals and expects to submit a 510K application to the FDA soon. President Adel Abdullah highlighted the excitement among industry partners for the upcoming validation studies, set to begin in September and conclude by November 2022.
Positron Corporation (OTC: POSC) announced the appointment of Christopher Reilly to lead its PET-CT Services and Systems Sales. With over 30 years of experience in SPECT imaging, Reilly aims to facilitate the transition from SPECT to PET imaging for hospitals and cardiology practices. The company will validate its new PET-CT device in collaboration with a leading healthcare organization over the next three months. President Adel Abdullah expressed confidence in Reilly's expertise, which is expected to support Positron's sales and marketing initiatives as it prepares to launch its new product.
FAQ
What is the current stock price of Positron (POSC)?
What is the market cap of Positron (POSC)?
